221 related articles for article (PubMed ID: 19883882)
1. Erythropoiesis-stimulating agents in anemia: use and misuse.
Dharmarajan TS; Widjaja D
J Am Med Dir Assoc; 2009 Nov; 10(9):607-16. PubMed ID: 19883882
[TBL] [Abstract][Full Text] [Related]
2. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
Dharmarajan TS; Widjaja D
Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
[TBL] [Abstract][Full Text] [Related]
3. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
4. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
Kapoian T
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
[TBL] [Abstract][Full Text] [Related]
5. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
Fishbane S; Jhaveri KD
Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
[TBL] [Abstract][Full Text] [Related]
6. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB; Coyne DW
Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
[TBL] [Abstract][Full Text] [Related]
7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
9. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
Malovrh M; Hojs N; Premru V
Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
[TBL] [Abstract][Full Text] [Related]
10. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
11. Changing patterns of anemia management in US hemodialysis patients.
Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietic stimulating agents.
Testa U
Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
[TBL] [Abstract][Full Text] [Related]
13. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
14. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
Moossavi S; Freedman BI
Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
[No Abstract] [Full Text] [Related]
15. Erythropoiesis-stimulating agents and heart failure.
Lipšic E; van der Meer P; van Veldhuisen DJ
Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
[TBL] [Abstract][Full Text] [Related]
16. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
18. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Doss S; Schiller B
Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
[TBL] [Abstract][Full Text] [Related]
19. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
20. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
